<![CDATA[Darzalex - Canadisk godkendelse]]>"TORONTO, Dec. 17, 2018 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved DARZALEX® (daratumumab), in combination with bortezomib, melphalan and prednisone (VMP), for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplantation.3 DARZALEX® is the first monoclonal antibody to be approved for newly diagnosed patients in Canada".

Link Preview Image
Health Canada Approves DARZALEX® (daratumumab) for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible

/CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved DARZALEX® (daratumumab), in combination with...

favicon

(www.newswire.ca)

]]>https://dev.proinvestor.com/forum/topic/440001/darzalex-canadisk-godkendelseRSS for NodeThu, 16 Jul 2026 23:55:27 GMTMon, 17 Dec 2018 16:43:48 GMT60